SDCBP and breast cancer: The results showed that Syntenin binds to kinases or receptors on the cytoplasmic membrane to activate the P38/NF-kB, ERK1/2 pathways, AKT pathways, P38/MAPK, leading to progression and metastasis in various malignant tumours, such as melanoma, glioma, breast cancer, small cell lung cancer and liver cancer [11–15].